Biogen's fourth-quarter net profit rose 48% to $305.6 million, as sales of its controversial multiple-sclerosis drug Tysabri continued to rise.
Biogen's fourth-quarter net profit rose 48% to $305.6 million, as sales of its controversial multiple-sclerosis drug Tysabri continued to rise.


Comments
Post new comment